Loading organizations...
Based in Vienna, Austria, Arkeon Biotechnologies is a biotechnology company that develops a proprietary gas fermentation process using naturally occurring archaea microbes to convert carbon dioxide into customizable protein ingredients and all twenty proteinogenic amino acids. The business operates as a B2B functional ingredient supplier, targeting food and beverage manufacturers, alternative protein companies, and the cosmetics industry with its sustainable production methods. Prior to filing for insolvency, the enterprise scaled its operations to include a 150 liter pilot production bioreactor at the Vienna Seestadt Innovation Hub. The firm raised over ten million euros in total funding, including an oversubscribed seed round, from a syndicate of venture capital and strategic investors like Synthesis Capital, ReGen Ventures, Square One Foods, and ICL Group. Arkeon Biotechnologies was founded in 2021 by Gregor Tegl, Simon Rittmann, and Guenther Bochmann.
Arkeon Biotechnologies has raised $4.0M across 1 funding round.
Arkeon Biotechnologies has raised $4.0M in total across 1 funding round.
Arkeon Biotechnologies has raised $4.0M in total across 1 funding round.
Arkeon Biotechnologies's investors include Golden Ventures, Tet Ventures, Ron Pragides.
Arkeon Biotechnologies was an Austrian biotech startup that developed a microbial gas fermentation process to convert industrial CO2 and hydrogen into all 20 proteinogenic amino acids, producing carbon-negative, clean-label protein ingredients for food applications.[1][2] It targeted the food industry by offering sustainable alternatives to traditional agriculture-dependent proteins, serving manufacturers seeking regenerative, land-independent solutions for food security and decarbonization.[1][2] The company achieved early milestones like opening a 150L pilot plant in Vienna's Seestadt Innovation Hub in 2023 and planning a 3000L demo facility, but filed for insolvency in late 2024, ending operations despite raising over $13 million (around €12 million) from investors including ICL, Synthesis Capital, and Blue Horizon.[3][4]
Founded in 2021 in Vienna, Austria, by Gregor Tegl (CEO), Günther Bochmann (CTO), Simon Rittmann (CSO), and Michael Mitsakos (CCO), Arkeon drew on the founders' combined 43 years in venture capital and biotechnology.[2][4] The idea emerged from a mission to decouple food production from resource-intensive agriculture by engineering archaea microbes—extremophile single-celled organisms—to ferment gases like CO2 and hydrogen directly into excreted amino acids, unlike competitors that retain them in biomass.[1][2] Early traction included €6.5 million in seed funding in 2022 and the 2023 pilot plant launch, earning workplace accolades like #1 Best Workplace in Austria, but scaling challenges led to insolvency filing announced by Tegl on LinkedIn in late 2024.[1][3][4][5]
Arkeon's technology stood out in the alternative protein space through these key features:
Arkeon rode the gas fermentation wave in synthetic biology, part of a niche cohort decoupling protein production from land and sugars amid global food security pressures and net-zero goals.[2][4] Timing aligned with rising CO2 utilization demands and EU sustainability mandates, bolstered by market forces like investor interest in regenerative agtech—evidenced by its €6.5M raise and pilots.[1][5] Though it failed to scale commercially, Arkeon advanced the ecosystem by validating archaea-based excretion tech, informing peers like those in precision fermentation and highlighting hurdles in techno-economics, regulations, and stakeholder navigation in an emerging field.[3][4]
Arkeon's insolvency underscores the high risks in gas fermentation startups, where promising tech meets scaling and funding gaps, yet its IP and lessons on CO2-to-protein conversion could fuel acquirers or founder spinouts.[3][4] Looking ahead, trends like cheaper green hydrogen, stricter emissions rules, and protein demand from population growth will propel similar ventures, potentially evolving the space toward viable industrial demos. Tegl's resolve—"every failure teaches us something new"—signals enduring momentum in sustainable biotech, tying back to Arkeon's core vision of nourishing people while revitalizing ecosystems through CO2 innovation.[3]
Arkeon Biotechnologies has raised $4.0M across 1 funding round. Most recently, it raised $4.0M Seed in December 2022.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Dec 1, 2022 | $4M Seed | — | Golden Ventures, TET Ventures, RON Pragides | Announced |
